Richard N Fedorak
Richard N Fedorak
Verified email at
TitleCited byYear
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, ...
New England Journal of Medicine 350 (9), 876-885, 2004
Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial
SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak, M Lukas, ...
Gastroenterology 130 (2), 323-333, 2006
Vedolizumab as induction and maintenance therapy for Crohn's disease
WJ Sandborn, BG Feagan, P Rutgeerts, S Hanauer, JF Colombel, ...
New England Journal of Medicine 369 (8), 711-721, 2013
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
WJ Sandborn, SB Hanauer, P Rutgeerts, RN Fedorak, M Lukas, ...
Gut 56 (9), 1232-1239, 2007
Methotrexate for the treatment of Crohn's disease
BG Feagan, J Rochon, RN Fedorak, EJ Irvine, G Wild, L Sutherland, ...
New England Journal of Medicine 332 (5), 292-297, 1995
Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice
KL Madsen, JS Doyle, LD Jewell, MM Tavernini, RN Fedorak
Gastroenterology 116 (5), 1107-1114, 1999
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
BG Feagan, RN Fedorak, EJ Irvine, G Wild, L Sutherland, AH Steinhart, ...
New England Journal of Medicine 342 (22), 1627-1632, 2000
VSL# 3 probiotic-mixture induces remission in patients with active ulcerative colitis
R Bibiloni, RN Fedorak, GW Tannock, KL Madsen, P Gionchetti, ...
The American journal of gastroenterology 100 (7), 1539, 2005
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan, GR Greenberg, G Wild, RN Fedorak, P Paré, JWD McDonald, ...
New England Journal of Medicine 352 (24), 2499-2507, 2005
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
EJ Irvine, B Feagan, J Rochon, A Archambault, RN Fedorak, A Groll, ...
Gastroenterology 106 (2), 287-296, 1994
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
W Reinisch, WJ Sandborn, DW Hommes, G D'Haens, S Hanauer, ...
Gut 60 (6), 780-787, 2011
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
WJ Sandborn, BG Feagan, RN Fedorak, E Scherl, MR Fleisher, S Katz, ...
Gastroenterology 135 (4), 1130-1141, 2008
The epidemiology of inflammatory bowel disease in Canada: a population-based study
CN Bernstein, A Wajda, LW Svenson, A MacKenzie, M Koehoorn, ...
The American journal of gastroenterology 101 (7), 1559, 2006
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease
S Schreiber, P Rutgeerts, RN Fedorak, M Khaliq–Kareemi, MA Kamm, ...
Gastroenterology 129 (3), 807-818, 2005
Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial
SR Targan, BG Feagan, RN Fedorak, BA Lashner, R Panaccione, ...
Gastroenterology 132 (5), 1672-1683, 2007
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
RN Fedorak, A Gangl, CO Elson, P Rutgeerts, S Schreiber, G Wild, ...
Gastroenterology 119 (6), 1473-1482, 2000
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
S Schreiber, RN Fedorak, OH Nielsen, G Wild, CN Williams, S Nikolaus, ...
Gastroenterology 119 (6), 1461-1472, 2000
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group
SJ Van Deventer, CO Elson, RN Fedorak
Gastroenterology 113 (2), 383-389, 1997
The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved …
A Barkun, S Sabbah, R Enns, D Armstrong, J Gregor, RNN Fedorak, ...
The American journal of gastroenterology 99 (7), 1238, 2004
Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora
KL Madsen, D Malfair, D Gray, JS Doyle, LD Jewell, RN Fedorak
Inflammatory bowel diseases 5 (4), 262-270, 1999
The system can't perform the operation now. Try again later.
Articles 1–20